Everest Medicines Limited

HK$27.02As of Sun 8 Nov 2026, 12:00 UTC
HKEX:1952Healthcare
Country Hong Kong
PE (Fwd) •••
TSR 6Y CAGR (11.90%)
Div yield —
ROE (1.18%)
Biotechnology
Beta (5Y) 1.55
PE TTM —
TSR TTM (44.83%)
Mkt cap HK$9.500B
ROIC (1.20%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$32
17.68%
(96.25%)
Hold 3|0|7|6|2
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.39
0.37
0.42
0.46
0.41%
(0.69%)
8.24%
14.97%
Revenue¥M
701.4
680.9
684.9
701.7
5.38%
0.71%
2.07%
1.54%
Peers (US$1.212B)
Cap (US$)
PE
1.093B
12.92x
1.214B
—
Capital
TTM
5Y
10Y
Leveragex
1.115
2.366
2.081
EBIT/Intx
6.676
0.193
0.196
Own earn%
62.97
(105.65)
(115.01)
Sh yield%
46.52
20.01
16.54
Owners
Insiders/Inst%
10.43
22.72
Short interest%
5.22
SBC / revenue%
3.04
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
6
Op margin range%
4–9
$1 testx
0.0
Incr. ROIC%
4